Search Results - "Barker, Roger"

Cell-based therapies for Parkinson disease—past insights and future potential by Barker, Roger A., Drouin-Ouellet, Janelle, Parmar, Malin

“…Key Points Dopaminergic drugs were established as an effective treatment for Parkinson disease (PD) in the 1960s, and are still the mainstay of therapy for…”
Get full text

Human Trials of Stem Cell-Derived Dopamine Neurons for Parkinson’s Disease: Dawn of a New Era by Barker, Roger A., Parmar, Malin, Studer, Lorenz, Takahashi, Jun

“…Stem cell-based therapies for Parkinson’s disease are moving into a new and exciting era, with several groups pursuing clinical trials with pluripotent stem…”
Get full text

Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease by Barker, Roger A, Prof, Barrett, Jessica, PhD, Mason, Sarah L, BSc, Björklund, Anders, PhD

“…Summary Clinical use of allografts of fetal ventral mesencephalic tissue as a treatment to replace dopaminergic neurons in patients with Parkinson's disease…”
Get full text

New approaches for brain repair—from rescue to reprogramming by Barker, Roger A., Götz, Magdalena, Parmar, Malin

“…The ability to repair or promote regeneration within the adult human brain has been envisioned for decades. Until recently, such efforts mainly involved…”
Get full text

Molecular Diversity of Midbrain Development in Mouse, Human, and Stem Cells by La Manno, Gioele, Gyllborg, Daniel, Codeluppi, Simone, Nishimura, Kaneyasu, Salto, Carmen, Zeisel, Amit, Borm, Lars E., Stott, Simon R.W., Toledo, Enrique M., Villaescusa, J. Carlos, Lönnerberg, Peter, Ryge, Jesper, Barker, Roger A., Arenas, Ernest, Linnarsson, Sten

“…Understanding human embryonic ventral midbrain is of major interest for Parkinson’s disease. However, the cell types, their gene expression dynamics, and their…”
Get full text

'The clocks that time us'—circadian rhythms in neurodegenerative disorders by Videnovic, Aleksandar, Lazar, Alpar S., Barker, Roger A., Overeem, Sebastiaan

“…Key Points Sleep and circadian disruption are common in Alzheimer disease, Parkinson disease and Huntington disease Symptoms of circadian disruption range from…”
Get full text

The basal forebrain cholinergic system as target for cell replacement therapy in Parkinson's disease by Björklund, Anders, Barker, Roger A

“…In recent years there has been a renewed interest in the basal forebrain cholinergic system as a target for the treatment of cognitive impairments in patients…”
Get full text

Sham surgery for the trialing of cell-based therapies to the CNS may not be necessary by Tabar, Viviane, Barker, Roger A

“…Sham surgery is often required for cell therapies adopting a randomized placebo-controlled double-blinded trial design. Using the case of dopamine neuron…”
Get more information

Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease by Kehagia, Angie A, PhD, Barker, Roger A, MRCP, Robbins, Trevor W, Prof

“…Summary Cognitive impairment in patients with Parkinson's disease is gaining increased clinical significance owing to the relative success of therapeutic…”
Get full text

The clinical heterogeneity of Parkinson's disease and its therapeutic implications by Greenland, Julia C., Williams‐Gray, Caroline H., Barker, Roger A.

“…Although Parkinson's disease (PD) is primarily a movement disorder, there are a range of associated nonmotor symptoms, including cognitive impairment,…”
Get full text

Parkinson disease and growth factors — is GDNF good enough? by Kirkeby, Agnete, Barker, Roger A.

“…Previous open-label trials testing glial cell line-derived neurotrophic factor (GDNF) family ligands in Parkinson disease have shown promising clinical…”
Get full text

Developing Stem Cell Therapies for Parkinson’s Disease: Waiting Until the Time Is Right by Barker, Roger A.

“…The ability to successfully replace lost nigral dopaminergic neurons in Parkinson’s disease (PD) has been clearly shown with fetal ventral mesencephalic…”
Get full text

Recent developments in the treatment of Parkinson's Disease [version 1; peer review: awaiting peer review] by Stoker, Thomas B, Barker, Roger A

“…Parkinson's disease (PD) is a common neurodegenerative disease typified by a movement disorder consisting of bradykinesia, rest tremor, rigidity, and postural…”
Get full text

Hunting out the autophagic problem in Huntington disease by Pircs, Karolina, Barker, Roger A., Jakobsson, Johan

“…Huntington disease is an inherited, progressive, incurable neurodegenerative disorder that primarily affects cells in the brain. Although the genetic basis for…”
Get full text

Cognitive impairment in Parkinson's disease: the dual syndrome hypothesis by Kehagia, Angie A, Barker, Roger A, Robbins, Trevor W

“…Research into the heterogeneous nature of cognitive impairment documented in patients with Parkinson's disease (PD) has focused on disentangling deficits that…”
Get more information

The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort by Williams-Gray, Caroline H, Mason, Sarah L, Evans, Jonathan R, Foltynie, Thomas, Brayne, Carol, Robbins, Trevor W, Barker, Roger A

“…Background Prognosis in Parkinson's disease (PD) remains poorly understood due to a lack of unbiased data on the natural history of treated PD. The CamPaIGN…”
Get full text

Intracellular SERS Nanoprobes For Distinction Of Different Neuronal Cell Types by Huefner, Anna, Kuan, Wei-Li, Barker, Roger A, Mahajan, Sumeet

“…Distinction between closely related and morphologically similar cells is difficult by conventional methods especially without labeling. Using nuclear-targeted…”
Get full text

Sleep and circadian rhythm regulation in early Parkinson disease by Breen, David P, Vuono, Romina, Nawarathna, Upekshani, Fisher, Kate, Shneerson, John M, Reddy, Akhilesh B, Barker, Roger A

“…Sleep disturbances are recognized as a common nonmotor complaint in Parkinson disease but their etiology is poorly understood. To define the sleep and…”
Get more information

Impact of GBA1 variants on long-term clinical progression and mortality in incident Parkinson’s disease by Stoker, Thomas B, Camacho, Marta, Winder-Rhodes, Sophie, Liu, Ganqiang, Scherzer, Clemens R, Foltynie, Thomas, Evans, Jonathan, Breen, David P, Barker, Roger A, Williams-Gray, Caroline H

“…IntroductionVariants in the GBA1 gene have been identified as a common risk factor for Parkinson’s disease (PD). In addition to pathogenic mutations (those…”
Get full text

The history and status of dopamine cell therapies for Parkinson's disease by Barker, Roger A, Björklund, Anders, Parmar, Malin

“…Parkinson's disease (PD) is characterized by the loss of the dopaminergic nigrostriatal pathway which has led to the successful development of drug therapies…”
Get full text